OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$1.05
-0.02 (-1.87%)
▼
5d:
-10.26%
30d:
-18.6%
90d:
-2.78%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $1.05, which is considered fair relative to its 30-day fair value range of $1.05 to $1.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.8) compared to its historical average (58.8). Remarkably, the market is currently pricing in an annual earnings decline of 9.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.80 (+738.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $1.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.80 (+738.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.05 -
$1.27
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 738.1% below Wall St target ($8.80)
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
- CAUTION: 5-day price weakness (-10.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.05 -
$1.27
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.23
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.75
Wall Street Target
$8.80
(+738.1%)
Revenue Growth (YoY)
49.4%
Profit Margin
28.0%
Valuation Discount vs History
-9.4% cheaper
PE vs Historical
43.8 vs 58.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.4%
(market-implied from PE analysis)
1-Year Target
$0.95
(-9%)
2-Year Target
$0.86
(-18%)
3-Year Target
$0.78
(-26%)
3-Yr Target (if PE normalizes)
(PE: 44→59)
$1.05
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.8, Growth: -94.6%)
$0.77
(+-27%)
Base:
(SPY PE: 20.2, Growth: -94.6%)
$0.35
(-66%)
Bear:
(PE: 17.1, Growth: -94.6%)
$0.30
(-71%)
📈
Valuation based on Current Earnings
Trailing PE: 2.55 | Current EPS (TTM): $0.42
Bull Case
$0.59
(-44%)
Analyst growth -50.0%, PE expands to 2.8
Base Case
$0.53
(-49%)
Market implied -50.0%, PE stable at 2.6
Bear Case
$0.73
(-31%)
Severe decline -20.0%, PE contracts to 2.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 43.8 to 58.8
Stabilization Target:
$1.41
(+34.4%)
PE Expansion Potential:
+34.4%
Share & Embed Analysis
Last updated: September 12, 2026 11:07 PM ET
Data refreshes hourly during market hours. Next update: 12:07 AM
Data refreshes hourly during market hours. Next update: 12:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
